Pancreatic lipase inhibitors from natural sources: Unexplored potential
Abstract
The prevalence of obesity is increasing at an alarming rate, but, unfortunately, only a few medications are currently on the market. Obesity is primarily regarded as a disorder of lipid metabolism and the enzymes involved in this process could be selectively targeted to develop antiobesity drugs. Recently, newer approaches for the treatment of obesity have involved inhibition of dietary triglyceride absorption via inhibition of pancreatic lipase (PL) as this is the major source of excess calories. Natural products provide a vast pool of PL inhibitors that can possibly be developed into clinical products. This article reviews various extracts and secondary metabolites from plants and microbial origin with PL inhibitory activity that can be focused for drug development programs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of pancreatic lipase decreases the absorption of lipids, which can reduce obesity.
“Therefore, inhibition of pancreatic lipase decreases the absorption of lipids, which can reduce obesity [11,12,13].”
From Separation and Lipid Inhibition Effects of a Novel Decapeptide from Chlorella pyenoidose (2019) · cites this paper as [11]
Cites
Structure of human pancreatic lipase
Winkler, F. K., D'Arcy, A., & Hunziker, W. H. (1990) · Nature · doi:10.1038/343771a0 · Cited by 1,227 · see citing works
Inhibitory Effects of Oolong Tea Polyphenols on Pancreatic Lipase in Vitro
Nakai, M., Fukui, Y., Asami, S., Toyoda‐Ono, Y., Iwashita, T., Shibata, H., Mitsunaga, T., Hashimoto, F., & Kiso, Y. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf047814+ · Cited by 493 · see citing works
Medicinal strategies in the treatment of obesity
Bray, G. A., & Tartaglia, L. A. (2000) · Nature · doi:10.1038/35007544 · Cited by 432 · see citing works
Structure of the pancreatic lipase–procolipase complex
TILBEURGH, H. V., Sarda, L., Verger, R., & Cambillau, C. (1992) · Nature · doi:10.1038/359159a0 · Cited by 378 · see citing works
Weibel, E. K., Hadváry, P., Hochuli, E., KUPFER, E., & Lengsfeld, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1081 · Cited by 343 · see citing works
Anti-obesity effect of Nelumbo nucifera leaves extract in mice and rats
Ono, Y., 服部, 英., Fukaya, Y., Imai, S., & Ohizumi, Y. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2005.12.036 · Cited by 337 · see citing works
Lipid metabolic enzymes: emerging drug targets for the treatment of obesity
Shi, Y., & Burn, P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1469 · Cited by 333 · see citing works
Inhibitory effects of grape seed extract on lipases
Moreno, D. A., Ilić, N., Poulev, A., Brasaemle, D., Fried, S. K., & Raskin, I. (2003) · Nutrition · doi:10.1016/s0899-9007(03)00167-9 · Cited by 267 · see citing works
Mechanism of hypolipidemic effect of crocin in rats: Crocin inhibits pancreatic lipase
Sheng, L., Qian, Z., Zheng, S., & Liang, X. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.05.038 · Cited by 266 · see citing works
Anti-obesity action of oolong tea
Han, L.-K., Takaku, T., Li, J., Kimura, Y., & Okuda, H. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800766 · Cited by 261 · see citing works
Lee, I., Lee, J. H., Baek, N., & Kim, D. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.2106 · Cited by 259 · see citing works
Jéquier, E. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802123 · Cited by 250 · see citing works
Carnosic acid, a new class of lipid absorption inhibitor from sage
Ninomiya, K., Matsuda, H., Shimoda, H., Nishida, N., Kasajima, N., Yoshino, T., Morikawa, T., & Yoshikawa, M. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.01.091 · Cited by 240 · see citing works
Saponins from Platycodi Radix Ameliorate High Fat Diet–Induced Obesity in Mice
Han, L.-K., Zheng, Y., Okuda, H., Xu, B., & Kimura, Y. (2002) · Journal of Nutrition · doi:10.1093/jn/132.8.2241 · Cited by 235 · see citing works
Yoshikawa, M., Shimoda, H., Matsuda, H., Nishida, N., & Takada, M. (2002) · Journal of Nutrition · doi:10.1093/jn/132.7.1819 · Cited by 233 · see citing works
Human digestive and metabolic lipases—A brief review
Mukherjee, M. (2003) · Journal of Molecular Catalysis B Enzymatic · doi:10.1016/s1381-1177(03)00052-3 · Cited by 217 · see citing works
The obesity pipeline: current strategies in the development of anti-obesity drugs
Cooke, D., & Bloom, S. R. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2136 · Cited by 212 · see citing works
Hesperidin as an Inhibitor of Lipases from Porcine Pancreas andPseudomonas
Kawaguchi, K., Mizuno, T., Aida, K., & Uchino, K. (1997) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.61.102 · Cited by 204 · see citing works
Platycodi Radix Affects Lipid Metabolism in Mice with High Fat Diet–Induced Obesity
Li-kun, H., Kimura, Y., Okuda, H., Xu, B., & Zheng, Y. (2000) · Journal of Nutrition · doi:10.1093/jn/130.11.2760 · Cited by 201 · see citing works
Anti-obesity Effect ofDioscorea nipponicaMakino with Lipase-inhibitory Activity in Rodents
Kwon, C.-S., Sohn, H. Y., Kim, S. H., Kim, J. H., Son, K. H., Lee, J. S., Lim, J., & Kim, J. (2003) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.67.1451 · Cited by 197 · see citing works
Liu, D., Wang, F., Liao, T., Tang, J., Steglich, W., Zhu, H., & Liu, J. (2006) · Organic Letters · doi:10.1021/ol062307u · Cited by 189 · see citing works
Anti-obesity effects of chikusetsusaponins isolated from Panax japonicus rhizomes
Han, L.-K., Zheng, Y., Yoshikawa, M., Okuda, H., & Kimura, Y. (2005) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-5-9 · Cited by 179 · see citing works
Anti-obesity effects in rodents of dietary teasaponin, a lipase inhibitor
Han, L.-K., Kimura, Y., Kawashima, M., Takaku, T., Taniyama, T., Hayashi, T., Zheng, Y.-N., & Okuda, H. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801747 · Cited by 176 · see citing works
Zhao, H., Sim, J., Shim, S. H., Ha, Y.-W., Kang, S. S., & Kim, Y. S. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802948 · Cited by 167 · see citing works
Pharmacological Therapy of Obesity: Past, Present, and Future
Weigle, D. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030151 · Cited by 148 · see citing works
Hochuli, E., KUPFER, E., MAURER, R., Meister, W., MERCADAL, Y., & Schmidt, K. W. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1086 · Cited by 146 · see citing works
Valilactone, an inhibitor of esterase, produced by actinomycetes.
Kitahara, M., Asano, M., NAGANAWA, H., Maeda, K., HAMADA, M., AOYAGI, T., UMEZAWA, H., IITAKA, Y., & Nakamura, H. (1987) · The Journal of Antibiotics · doi:10.7164/antibiotics.40.1647 · Cited by 142 · see citing works
Emerging Therapeutic Strategies for Obesity
Foster‐Schubert, K. E., & Cummings, D. E. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0041 · Cited by 139 · see citing works
Screening of lipase inhibitors from marine algae
Bitou, N., Ninomiya, M., Tsujita, T., & Okuda, H. (1999) · Lipids · doi:10.1007/s11745-999-0383-7 · Cited by 138 · see citing works
Hypolipemic Effect of Cyclocarya paliurus (Batal) Iljinskaja in Lipid-Loaded Mice.
Kurihara, H., Asami, S., Shibata, H., Fukami, H., & Tanaka, T. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.383 · Cited by 126 · see citing works
Yamamoto, M., Shimura, S., Itoh, Y., Ohsaka, T., Egawa, M., & Inoue, S. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801222 · Cited by 123 · see citing works
Yoshizumi, K., Hirano, K., Ando, H., Hirai, Y., Ida, Y., Tsuji, T., Tanaka, T., Satouchi, K., & Terao, J. (2005) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf052047f · Cited by 118 · see citing works
Treatment of obesity: an update on anti‐obesity medications
Halpern, A., & Mancini, M. C. (2003) · Obesity Reviews · doi:10.1046/j.1467-789x.2003.00083.x · Cited by 115 · see citing works
Hofbauer, K. G. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0802124 · Cited by 113 · see citing works
Melnikova, I., & Wages, D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2037 · Cited by 110 · see citing works
Effects of Arachis hypogaea nutshell extract on lipid metabolic enzymes and obesity parameters
Moreno, D. A., Ilić, N., Poulev, A., & Raskin, I. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.11.012 · Cited by 105 · see citing works
In vitro inhibitory effect of triterpenoidal saponins from platycodi radix on pancreatic lipase
Xu, B. J., Han, L., Zheng, Y. N., Lee, J. H., & Sung, C. K. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977712 · Cited by 103 · see citing works
New Biologically Active Triterpenoid Saponins from Scabiosa tschiliensis
Zheng, Q., Koike, K., Han, L.-K., Okuda, H., & Nikaido, T. (2004) · Journal of Natural Products · doi:10.1021/np0304722 · Cited by 103 · see citing works
Kimura, H., Ogawa, S., Jisaka, M., Kimura, Y. N., Katsube, T., & Yokota, K. (2006) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2006.02.031 · Cited by 88 · see citing works
Flavan dimers with lipase inhibitory activity from Cassia nomame
Hatano, T., Yamashita, A., Hashimoto, T., Ito, H., Kubo, N., Yoshiyama, M., Shimura, S., Itoh, Y., Okuda, T., & Yoshida, T. (1997) · Phytochemistry · doi:10.1016/s0031-9422(97)00367-1 · Cited by 85 · see citing works
Ebelactone, an inhibitor of esterase, produced by actinomycetes.
UMEZAWA, H., AOYAGI, T., Uotani, K., HAMADA, M., TAKEUCHI, T., & Takahashi, S. (1980) · The Journal of Antibiotics · doi:10.7164/antibiotics.33.1594 · Cited by 85 · see citing works
3-Methylethergalangin Isolated from Alpinia officinarum Inhibits Pancreatic Lipase
Shin, J., Han, M. J., & Kim, D. (2003) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.26.854 · Cited by 83 · see citing works
Obesity drugs in clinical development.
Halford, J. C. G. (2006) · PubMed · Cited by 79 · see citing works
[1] Inhibition of lipid absorption as an approach to the treatment of obesity
Thomson, A. B. R., Pover, A. D., Keelan, M., et al. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)86003-x · Cited by 79 · see citing works
Esterastin, an inhibitor of esterase, produced by Actinomycetes.
UMEZAWA, H., AOYAGI, T., Hazato, T., Uotani, K., Kojima, F., HAMADA, M., & TAKEUCHI, T. (1978) · The Journal of Antibiotics · doi:10.7164/antibiotics.31.639 · Cited by 74 · see citing works
Pharmacological treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200024 · Cited by 73 · see citing works
Zhao, H. L., & Kim, Y. S. (2004) · Archives of Pharmacal Research · doi:10.1007/bf02975852 · Cited by 66 · see citing works
Mutoh, M., Nakada, N., Matsukuma, S., Ohshima, S., Yoshinri, K., Watanabe, J. A., & Arisawa, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.1369 · Cited by 54 · see citing works
Daio-Orengedokuto Inhibits HMG-CoA Reductase and Pancreatic Lipase.
Kim, Y. S., Jung, E.-A., Shin, J., Chang, J.-C., Yang, H.-K., Kim, N., Cho, K., Bae, H.-S., Moon, S., & Kim, D. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.1442 · Cited by 53 · see citing works
Addressing the Unmet Medical Need for Safe and Effective Weight Loss Therapies
ARBEENY, C. M. (2004) · Obesity Research · doi:10.1038/oby.2004.150 · Cited by 49 · see citing works
Potential Anti-obesity and Lipid Lowering Natural Products: A Review
Bhutani, K. K., Birari, R. B., & Kapat, K. (2007) · Natural Product Communications · doi:10.1177/1934578x0700200316 · Cited by 46 · see citing works
Self-citationEmerging aspects of pharmacotherapy for obesity and metabolic syndrome
Nisoli, E., & Carruba, M. O. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.02.004 · Cited by 44 · see citing works
The Psychopharmacology of Appetite: Targets for Potential Anti-Obesity Agents
Halford, J. C. G., Cooper, G. D., Dovey, T. M., et al. (2003) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015033477695 · Cited by 32 · see citing works
Panclicins, novel pancreatic lipase inhibitors. II. Structural elucidation.
YOSHINARI, K., Aoki, M., Ohtsuka, T., NAKAYAMA, N., Itezono, Y., Mutoh, M., Watanabe, J. A., & Yokose, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.1376 · Cited by 32 · see citing works
Microbial metabolites with inhibitory activity against lipid metabolism
Tomoda, H., Namatame, I., & Ōmura, S. (2002) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.78.217 · Cited by 29 · see citing works
Investigational therapies in the treatment of obesity
Mancini, M. C., & Halpern, A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.897 · Cited by 28 · see citing works
Current pharmacological approaches to the treatment of obesity
Hauner, H. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801711 · Cited by 26 · see citing works
Novel molecular targets for the treatment of obesity
Strader, C. D., Hwa, J. J., van Heek, M., & Parker, E. M. (1998) · Drug Discovery Today · doi:10.1016/s1359-6446(98)01189-1 · Cited by 24 · see citing works
Antiobesity Therapy: Emerging Drugs and Targets
Das, S. K., & Chakrabarti, R. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776872880 · Cited by 21 · see citing works
Cairns, E. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03375-1 · Cited by 18 · see citing works
Search for Obesity Drugs: Targeting Central and Peripheral Pathways
Srivastava, R. A. K., & Srivastava, N. (2004) · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents · doi:10.2174/1568013043357806 · Cited by 12 · see citing works
Harrold, J. A., Williams, G., & Wong, S. (2003) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/1568015033477785 · Cited by 8 · see citing works
Combating Obesity by Targeting Nuclear Receptors
Szewczyk, J., & Sternbach, D. D. (2005) · Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents · doi:10.2174/1568013053005427 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Possible anti-obesity therapeutics from nature--a review
Yun, J. W. (2010) · Phytochemistry · doi:10.1016/j.phytochem.2010.07.011 · Cited by 619 · see citing works
Hypoglycemic and antilipidemic properties of kombucha tea in alloxan-induced diabetic rats
Aloulou, A., Hamden, K., Elloumi, D., Ali, M. B., Hargafi, K., Jaouadi, B., Ayadi, F., Elfeki, A., & Ammar, E. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-63 · Cited by 201 · see citing works
Yuan, Y., Xu, X., Jing, C., Zou, P., Zhang, C., & Li, Y. (2018) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.11.061 · Cited by 197 · see citing works
Grove, K. A., Sae‐Tan, S., Kennett, M. J., & Lambert, J. D. (2012) · Obesity · doi:10.1038/oby.2011.139 · Cited by 139 · see citing works
Angptl4 serves as an endogenous inhibitor of intestinal lipid digestion
Mattijssen, F., Alex, S., Swarts, H. J., Groen, A. K., van Schothorst, E. M., & Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.004 · Cited by 88 · see citing works
Separation and Lipid Inhibition Effects of a Novel Decapeptide from Chlorella pyenoidose
Zhang, R., Chen, J., Mao, X., Qi, P., & Zhang, X. (2019) · Molecules · doi:10.3390/molecules24193527 · Cited by 34 · see citing works
Ansari, P., Khan, J. T., Choudhary, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel-Wahab, Y. H. A., & Flatt, P. R. (2024) · doi:10.20944/preprints202408.1739.v1 · Cited by 89 · see citing works
- Authors
- Birari, R. B., & Bhutani, K. K.
- Affiliations
- National Institute of Pharmaceutical Education and Research (IN)
- Corresponding author
- Bhutani, Kamlesh K.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2007-10
- Volume
- 12
- Issue
- 19-20
- Pages
- 879-889
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2066197031
- Cited by
- 871
- References
- 63
- Citations by year
- 2026: 25 · 2025: 39 · 2024: 45 · 2023: 71 · 2022: 59 · 2021: 68 · 2020: 52 · 2019: 58 · 2018: 59 · 2017: 59 · 2016: 54 · 2015: 57 · 2014: 56 · 2013: 58 · 2012: 39
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioactive natural compounds
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
- Keywords
- pancreatic lipase inhibitors, obesity, anti-obesity drugs, natural products, plant extracts, microbial secondary metabolites, lipid metabolism, drug development
- MeSH terms
- Biological Products, Flavonoids, Humans, Lactones, Lipase, Obesity, Pancreas, Phenols, Plant Extracts, Plants, Medicinal, Saponins, Terpenes, Lipid Metabolism, Polyphenols
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review